SWOG clinical trial number
CTSU/C80702

A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

Closed
Phase
Abbreviated Title
Ph III Colon FOLFOX + Celecoxib/Placebo
Status Notes
This study will be permanently closed to accrual effective 11/20/15 at 4:30 P.M. E.S.T..
Activated
08/15/2010
Closed
11/20/2015
Participants
CTSU

Research committees

Gastrointestinal Cancer

Treatment

5-Fluorouracil Leucovorin Calcium Oxaliplatin Celecoxib Placebo

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2021

Prognostic value of tumor deposits in stage III colon cancer patients, a post hoc analysis of CALGB/SWOG 80702 phase III study

R Cohen;Q Shi;J Meyers;Z Jin;M Svrcek;C Fuchs;F Couture;P Kuebler;J Bendell;P Kumar;D Lewis;B Tan;M Bertagnolli;H Hochster;C Blanke;E O'Reilly;A Shields;J Meyerhardt J Clin Oncol 39, 2021 (suppl 3; abstr 10); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), rapid abstract presentation

2020

Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702

J Meyerhardt;Q Shi;C Fuchs;D Niedzwiecki;T Zemla;P Kumthekar;K Guthrie;F Couture;JP Kuebler;J Bendell;P Kumar;D Lewis;B Tan;M Bertagnolli;A Grothey;H Hochster;R Goldberg;A Venook;CD Blanke;AF Shields J Clin Oncol 38: 2020 (suppl; abstr 4003);American Society of Clinical Oncology Annual Meeting (5/29/2020 - 6/2/2020, Chicago, IL), oral

Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration

A Sobrero;T Andre;J Meyerhardt;A Grothey;T Iveson;T Yoshino;I Souglakos;J Meyers;R Labianca;M Saunders;D Vernerey;T Yamanaka;I Boukovinas;E Georgoulias;V Torri;A Harkin;J Taieb;A Shields;Q Shi J Clin Oncol 38: 2020 (suppl; abstr 4004); American Society of Clinical Oncology 2020 Annual Meeting, oral

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer: Final results from the IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration

T Andre;J Meyerhardt;T Iveson;A Sobrero;T Yoshino;I Souglakos;D Niedzwiecki;M Saunders;R Labianca;T Yamanaka;I Boukovinas;D Vernerey;J Meyers;A Harkin;V Torri;E Georgoulias;E Oki;J Taieb;AF Shields;Q Shi Lancet Oncology Dec;21(12):1620-1629. doi: 10.1016/S1470-2045(20)30527-1.

PMid: PMID33271092 | PMC number: PMC7786835

2018

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

A Grothey;A Sobrero;A Shields;T Yoshino;J Paul;J Taieb;I Souglakos;Q Shi;R Kerr;R Labianca;J Meyerhardt;D Vernerey;T Yamanaka;I Boukovinas;JP Meyers;LA Renfro;D Niedzwiecki;V Torri;D Sargent;T Andre;T Iveson New England Journal of Medicine Mar 29;378(13):1177-1188

PMid: PMID29590544 | PMC number: PMC6426127

Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration

A Shields;FS Ou;J Paul;A Sobrero;T Yoshino;J Taieb;I Souglakos;Q Shi;R Kerr;R Labianca;T Yamanaka;D Vernerey;I Boukovinas;T Kato;V Torri;S Kakolyris;T Andre;T Grothey;J Meyerhardt;T Iveson J Clin Oncol 36, 2018 (suppl; abstr 3599); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer? [Special Article; Review]

A Sobrero;A Grothey;T Iveson;R Labianca;T Yoshino;J Taieb;T Maughan;M Buyse;T Andre;J Meyerhardt;A Shields;I Souglakos;J Douillard;A Cervantes Annals of Oncology May 1;29(5):1099-1107

PMid: PMID29438451 | PMC number: PMC6864492

2017

Prospective pooled analysis of six phase III trials investigating duration of adjuvant oxaliplatin-based therapy (3 versus 6 months) for patients with stage III colon cancer: The IDEA(International Duration Evaluation of Adjuvant chemotherapy) collaboration

Q Shi;A Sobrero;A Shields;T Yoshino;J Taieb;I Souglakos;R Kerr;R Labianca;J Meyerhardt;F Bonnetain;T Watanabe;I Mpoukovinas;L Renfro;A Grothey;D Niedzwiecki;V Torri;T Andre;D Sargent J Clin Oncol 35, 2017 (suppl; abstr LBA1); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral, plenary

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration

A Grothey;AF Sobrero;JA Meyerhardt;T Yoshino;J Paul;J Taieb;I Soougklakos;R Kerr;R Labianca;A Shields;F Bonnetain;T Yamanaka;I Boukovinas;Q Shi;JP Meyers;D Niedzwiecki;V Torri;DJ Sargent;T Andre;T Iveson European Society of Medical Oncology (ESMO) 2017 (September 8-12, 2017, Madrid, Spain), poster

2014

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration: a prospective pooled analysis of > 11,500 patients from 6 Phase III trials of adjuvant therapy duration with FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) for stage III colon cancer

D Sargent;J Paul;A Sobrero;T Andre;A Shields;T Yoshino;I Souglakos;T Iveson;R Labianca;J Taieb;JA Meyerhardt;A Ohtsu;A Grothey Annals of Oncology 25 (Suppl 4): iv1 - mdu438.66; ESMO 2014 Congress (September 26-30, 2014, Madrid, Spain), poster presentation;

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/EA2176
SWOG Clinical Trial Number
CTSU/A021806

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Research Committee(s)
Gastrointestinal Cancer
Activated
07/01/2020
Open